Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 30 12:28PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.04 Insider Own0.37% Shs Outstand10.38M Perf Week245.12%
Market Cap15.05M Forward P/E- EPS next Y-0.75 Insider Trans0.00% Shs Float10.34M Perf Month201.29%
Income-8.07M PEG- EPS next Q-0.20 Inst Own8.68% Short Float / Ratio0.52% / 0.81 Perf Quarter222.11%
Sales0.20M P/S75.23 EPS this Y82.74% Inst Trans-10.09% Short Interest0.05M Perf Half Y101.32%
Book/sh0.41 P/B3.56 EPS next Y9.64% ROA-55.21% Target Price3.00 Perf Year-83.14%
Cash/sh0.99 P/C1.46 EPS next 5Y1.00% ROE-307.41% 52W Range0.38 - 10.35 Perf YTD-78.62%
Dividend- P/FCF- EPS past 5Y22.69% ROI-139.66% 52W High-86.00% Beta1.36
Dividend %- Quick Ratio1.99 Sales past 5Y93.09% Gross Margin-232.18% 52W Low281.45% ATR0.14
Employees15 Current Ratio1.99 Sales Q/Q- Oper. Margin-4949.44% RSI (14)91.38 Volatility6.32% 8.31%
OptionableNo Debt/Eq0.75 EPS Q/Q86.09% Profit Margin-4037.19% Rel Volume1893.50 Prev Close0.42
ShortableNo LT Debt/Eq0.37 EarningsNov 13 BMO Payout- Avg Volume67.13K Price1.45
Recom1.00 SMA20235.92% SMA50194.52% SMA20032.42% Volume61,469,459 Change248.94%
Date Action Analyst Rating Change Price Target Change
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Today 11:07AM
Nov-17-23 04:00PM
Nov-13-23 08:12AM
07:30AM Loading…
Oct-20-23 04:00PM
Oct-16-23 07:30AM
Oct-13-23 09:00AM
Oct-06-23 09:00AM
Sep-25-23 07:30AM
Sep-22-23 04:00PM
Aug-24-23 05:30AM
Aug-21-23 07:30AM
10:05AM Loading…
Aug-11-23 10:05AM
Aug-10-23 07:30AM
Jul-19-23 07:13AM
Jul-11-23 07:30AM
Jun-29-23 08:07AM
Jun-02-23 09:00AM
May-30-23 05:00AM
May-16-23 07:30AM
May-15-23 07:30AM
May-11-23 07:30AM
May-09-23 04:05PM
May-05-23 09:05AM
May-04-23 03:54PM
May-03-23 07:30AM
07:30AM Loading…
May-01-23 07:30AM
Apr-24-23 09:18AM
Apr-14-23 01:39PM
Apr-05-23 07:30AM
Apr-03-23 11:11AM
Mar-31-23 07:30AM
Mar-09-23 07:30AM
Feb-16-23 11:54AM
Feb-14-23 09:55AM
Feb-09-23 07:30AM
Jan-19-23 07:30AM
Jan-12-23 08:30AM
Jan-09-23 05:36AM
Dec-23-22 04:01PM
Dec-20-22 08:30AM
Dec-19-22 07:30AM
Dec-16-22 12:09PM
Dec-15-22 07:30AM
Dec-06-22 08:30AM
Nov-16-22 10:28AM
Nov-15-22 07:30AM
Nov-14-22 05:39AM
Nov-13-22 07:12AM
Nov-11-22 09:30AM
Nov-10-22 07:30AM
Nov-07-22 09:30AM
Oct-28-22 06:45AM
Oct-27-22 07:30AM
Oct-25-22 07:30AM
Oct-24-22 09:30AM
Oct-21-22 09:30AM
Oct-20-22 08:30AM
Oct-17-22 10:16AM
Oct-13-22 08:30AM
Sep-23-22 07:30AM
Sep-12-22 08:30AM
Sep-08-22 07:30AM
Sep-06-22 07:30AM
Aug-22-22 09:54AM
Aug-18-22 09:40AM
Aug-16-22 07:00AM
Aug-12-22 07:30AM
Jul-27-22 07:30AM
Jul-26-22 09:27AM
Jul-25-22 09:16AM
Jul-20-22 03:16PM
Jun-28-22 07:30AM
Jun-27-22 06:30AM
Jun-23-22 07:30AM
Jun-07-22 08:30AM
Jun-03-22 08:00AM
Jun-01-22 07:30AM
May-23-22 07:30AM
May-19-22 10:30AM
May-18-22 07:30AM
May-13-22 07:30AM
Apr-19-22 07:30AM
Mar-31-22 10:36AM
Mar-29-22 07:30AM
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.